Patents by Inventor Stephen J. Shuttleworth

Stephen J. Shuttleworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-(2-(BENZO[D]THIAZOL-2-YL)-2-(PHENYLSUFONAMIDO)ETHYL)BENZIMIDAMIDE DERIVATIVES AND RELATED COMPOUNDS AS TMPRSS2 INHIBITORS FOR THE TREATMENT OF VIRAL INFECTIONS
    Publication number: 20240132457
    Abstract: The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infections. Exemplary compounds are e.g. 3-(2-(benzo[d]thiazol-2-yl)-2-(phenylsufonamido)ethyl)benzimidamide (example 1), as well as derivatives and related compounds thereof.
    Type: Application
    Filed: June 2, 2021
    Publication date: April 25, 2024
    Inventor: Stephen J. Shuttleworth
  • MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN
    Publication number: 20230322722
    Abstract: Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.
    Type: Application
    Filed: August 25, 2021
    Publication date: October 12, 2023
    Inventors: William Greenlee, Stephen J. Shuttleworth, Keith Wilson
  • Histone deacetylase inhibitors
    Patent number: 10870624
    Abstract: The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: December 22, 2020
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. L. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
  • Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
    Patent number: 10442815
    Abstract: The invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof and/or stereoisomers thereof. The compounds of the invention are useful in therapy.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 15, 2019
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Franck A. Silva, Alexander R. L. Cecil, Rikki P. Alexander, Alice E. Gatland, Daniel J. Finnemore
  • Histone deacetylase inhibitors and their use in therapy
    Patent number: 10150763
    Abstract: A compound of the formula:(I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: December 11, 2018
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
  • COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR
    Publication number: 20180243317
    Abstract: The invention relates to a pharmaceutical composition comprising at least one PI3K inhibitor of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor such as a compound of Formula II or a pharmaceutically acceptable salt thereof; or at least one PI3K inhibitor such as a compound of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor of Formula II or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 19, 2016
    Publication date: August 30, 2018
    Inventors: Stephen J. Shuttleworth, Andrew D. Whale
  • TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS
    Publication number: 20180244685
    Abstract: The invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof and/or stereoisomers thereof. The compounds of the invention are useful in therapy.
    Type: Application
    Filed: August 19, 2016
    Publication date: August 30, 2018
    Inventors: Stephen J. Shuttleworth, Franck A. Silva, Alexander R.L. Cecil, Rikki P. Alexander, Alice E. Gatland, Daniel J. Finnemore
  • NOVEL HISTONE DEACETYLASE INHIBITORS
    Publication number: 20180170876
    Abstract: The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 21, 2018
    Inventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. L. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
  • Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
    Patent number: 9938290
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: April 10, 2018
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Alexander R. Liam Cecil, Thomas J. Hill, Franck A. Silva
  • NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY
    Publication number: 20180086750
    Abstract: A compound of the formula: (I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.
    Type: Application
    Filed: May 8, 2017
    Publication date: March 29, 2018
    Inventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
  • TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS
    Publication number: 20180009826
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.
    Type: Application
    Filed: January 19, 2017
    Publication date: January 11, 2018
    Inventors: Stephen J. Shuttleworth, Alexander R. Liam Cecil, Thomas J. Hill, Franck A. Silva
  • Histone deacetylase inhibitors
    Patent number: 9862685
    Abstract: The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: January 9, 2018
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. L. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
  • Histone deacetylase inhibitors and their use in therapy
    Patent number: 9676765
    Abstract: A compound of the formula: (I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: June 13, 2017
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. Cecil, Somhairle Maccormick, William J. Nodes, Franck A. Silva
  • Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
    Patent number: 9580442
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: February 28, 2017
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Alexander R. Liam Cecil, Thomas J. Hill, Franck A. Silva
  • TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS
    Publication number: 20160108057
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable sail thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.
    Type: Application
    Filed: October 22, 2015
    Publication date: April 21, 2016
    Inventors: Stephen J. Shuttleworth, Alexander R. Liam, Thomas J. Hill, Franck A. Silva
  • NOVEL HISTONE DEACETYLASE INHIBITORS
    Publication number: 20160096804
    Abstract: The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.
    Type: Application
    Filed: May 12, 2014
    Publication date: April 7, 2016
    Inventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
  • Pharmaceutical compounds
    Patent number: 8946217
    Abstract: Fused pyrimidines of formula (I): wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: February 3, 2015
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Stephen J. Shuttleworth, Adrian J. Folkes, Irina S. Chuckowree, Nan Chi Wan, Timothy C. Hancox, Stewart J. Baker, Sukhjit Sohal, Mohammed A. Latif
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20140294946
    Abstract: Fused pyrimidines of formula (I): wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Stephen J. Shuttleworth, Adrian J. Folkes, Irina S. Chuckowree, Nan Chi Wan, Timothy C. Hancox, Stewart J. Baker, Sukhjit Sohal, Mohammed A. Latif
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20130317017
    Abstract: Fused pyrimidines of formula (I): wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
    Type: Application
    Filed: July 25, 2013
    Publication date: November 28, 2013
    Applicant: F. Hoffman-La Roche AG
    Inventors: Stephen J. Shuttleworth, Adrian J. Folkes, Irina S. Chuckowree, Nan Chi Wan, Timothy C. Hancox, Stewart J. Baker, Sukhjit Sohal, Mohammed A. Latif
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20120258966
    Abstract: Fused pyrimidines of formula (I): wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
    Type: Application
    Filed: March 8, 2012
    Publication date: October 11, 2012
    Applicants: F. HOFFMAN-LA ROCHE AG, PIRAMED LIMITED
    Inventors: Stephen J. Shuttleworth, Adrian J. Folkes, Irina S. Chuckowree, Nan Chi Wan, Timothy C. Hancox, Stewart J. Baker, Sukhjit Sohal, Mohammed A. Latif